Gastro-intestinal autoimmunity: Preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells

Immunologic Research

Volumn 56, Issue 2-3, 2013, Pages 241-248

  Voswinkel, Jan ^a   Francois, Sabine ^a,b   Gorin, Norbert Claude ^a   Chapel, Alain ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

Author keywords

Colitis; Fistulization; Immunology; Inflammatory bowel diseases; MSC; Stem cells

Indexed keywords

FIBRIN GLUE;

ARTICLE; AUTOIMMUNITY; BLEEDING; BONE MARROW; CONNECTIVE TISSUE DISEASE; CROHN DISEASE; DIARRHEA; FIBROSIS; GRAFT VERSUS HOST REACTION; HUMAN; INFLAMMATION; LYMPHOCYTE SUBPOPULATION; MESENCHYMAL STROMA CELL; NONHUMAN; PAIN; PRIORITY JOURNAL; RECTOVAGINAL FISTULA; REGULATORY T LYMPHOCYTE; TISSUE INJURY; ULCERATIVE COLITIS;

ADULT STEM CELLS; ANIMALS; AUTOIMMUNITY; DIGESTIVE SYSTEM FISTULA; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 84879555325     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8397-8     Document Type: Article

References (40)

1. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11-20. (Pubitemid 38019084)
2. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389-97. (Pubitemid 36222968)
3. Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12:47-57. (Pubitemid 40576763)
4. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation. 2003;76:1208-13. (Pubitemid 37339646)
5. Djouad F, Bony C, Haupl T, et al. Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Res Ther. 2005;7:R1304-15.
6. De Bari C, Dell'Accio F, Luyten FP. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum. 2001;44:85-95. (Pubitemid 32113122)
7. Noel D, Caton D, Roche S, et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res. 2008;314:1575-84.
8. Fickert S, Fiedler J, Brenner RE. Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting. Osteoarthr Cartil. 2003;11:790-800. (Pubitemid 37407595)
9. Malgieri A, Kantzari E, Patrizi MP, Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med. 2010;3:248-69.
10. Voswinkel J, Chapel A. Mesenchymal stem cells and rheumatism: state of the art. Z Rheumatol. 2012;71:619-23.
11. Beggs KJ, Lyubimov A, Borneman JN, et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transpl. 2006;15:711-21. (Pubitemid 46095254)
12. Rubio D, Garcia-Castro J, Martin MC, et al. Spontaneous human adult stem cell transformation. Cancer Res. 2005;65:3035-9. (Pubitemid 40524580)
13. Tarte K, Gaillard J, Lataillade JJ, et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood. 2010;115:1549-53.
14. Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142-9. (Pubitemid 47535900)
15. Dryden GW. Overview of stem cell therapy for Crohn's disease. Expert Opin Biol Ther. 2009;9:841-7.
16. Dryden GW Jr. Overview of biologic therapy for Crohn's disease. Expert Opin Biol Ther. 2009;9:967-74.
17. Ditschkowski M, Einsele H, Schwerdtfeger R, et al. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation. 2003;75:1745-7. (Pubitemid 36629161)
18. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416-23. (Pubitemid 40933870)
19. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79-86.
20. Garcia-Olmo D, Herreros D, Pascual M, et al. Treatment of enterocutaneous fistula in Crohn's disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis. 2009;24:27-30.
21. García-Olmo D, Herreros D, De-La-Quintana P, et al. Adipose-derived stem cells in Crohn's rectovaginal fistula. Case Rep Med. 2010;2010:961758. doi: 10.1155/2010/961758.
22. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59:1662-9.
23. Lazebnik LB, Konopliannikov AG, Kniazev OV, et al. Use of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory diseases. Ter Arkh. 2010;82:38-43.
24. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulizing Crohn's disease. Gut. 2011;60:788-98.
25. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119-26. (Pubitemid 46743372)
26. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390-7. (Pubitemid 43847148)
27. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-86. (Pubitemid 351626841)
28. Andreyev HJ, Wotherspoon A, Denham JW. Hauer-JensenM. "Pelvic radiation disease": new understanding and new solutions for a new disease in the era of cancer survivorship. Scand J Gastroenterol. 2011;46:389-97.
29. Potten CS, Owen G, Roberts SA. The temporal and spatial changes in cell proliferation within the irradiated crypts of the murine small intestine. Int J Radiat Biol. 1990;57:185-99. (Pubitemid 20027040)
30. Gaugler MH, Vereycken-Holler V, Squiban C, Vandamme M, Vozenin-Brotons MC, Benderitter M. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res. 2005;163:479-87. (Pubitemid 41490643)
31. Milliat F, Francois A, Isoir M, et al. Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: implication in radiation-induced vascular damages. Am J Pathol. 2006;169:1484-95. (Pubitemid 351194379)
32. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001;293:293-7. (Pubitemid 32694744)
33. Zhang J, Gong JF, Zhang W, Zhu WM, Li JS. Effects of transplanted bone marrow mesenchymal stem cells on the irradiated intestine of mice. J Biomed Sci. 2008;15:585-94.
34. Semont A, Francois S, Mouiseddine M, et al. Mesenchymal stem cells increase self-renewal of small intestinal epithelium and accelerate structural recovery after radiation injury. Adv Exp Med Biol. 2006;585:19-30.
35. Semont A, Mouiseddine M, Francois A, et al. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. Cell Death Differ. 2010;17:952-61.
36. Kudo K, Liu Y, Takahashi K, et al. Transplantation of mesenchymal stem cells to prevent radiation-induced intestinal injury mice. J Radiat Res. 2010;251:73-9.
37. Gao Z, Zhang Q, Han Y, et al. Mesenchymal stromal cell-conditioned medium prevents radiation-induced small intestine injury in mice. Cytotherapy. 2012;14:267-73.
38. Lorenzi B, Pessina F, Lorenzoni P, et al. Treatment of experimental injury of anal sphincters with primary surgical repair and injection of bone marrow-derived mesenchymal stem cells. Dis Colon Rectum. 2008;51:411-20.
39. Saha S, Bhanja P, Kabarriti R, Liu L, Alfieri AA, Guha C. Bone marrow stromal cell transplantation mitigates radiation-induced gastrointestinal syndrome in mice. PLoS ONE. 2011;6:e24072.
40. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204-19.